WBA Walgreens NASDAQ $11.98 pre-market Mar 23 2026: watch 50-day test

WBA stock opened pre-market at $11.98 on Mar 23 2026, ranking among the pre-market most active names on NASDAQ. Volume is heavy at 452081061.00 shares versus an average of 16940296.00, pushing relative volume to 26.69. Traders are watching the 50-day average at $11.66 and the 200-day average at $10.81 for a short-term trend test. This report tracks valuation, technicals, analyst signals, and a Meyka AI forecast to frame near-term opportunity and risk in the United States healthcare retail sector.

WBA stock trading snapshot

Pre-market price is $11.98, up 0.06 or 0.50% from the previous close of $11.92. Day low and high are both $11.98 in early trading. Year high is $13.25 and year low is $8.08. Market capitalization stands at 10369421068.00 USD with 865561024.00 shares outstanding. Average volume is 16940296.00, while today’s volume is running at 452081061.00, signaling heavy trading interest and potential short-term volatility.

Financial and valuation metrics

Walgreens Boots Alliance, Inc. reports EPS of -7.29 and a trailing PE of -1.64, reflecting recent losses. Price-to-sales is 0.09 and price-to-book is 1.44. Free cash flow per share is -0.59 and operating cash flow per share is 0.28, indicating constrained cash generation. Dividend per share is 0.25, yielding 2.09%. Debt-to-equity is elevated at 4.04, and interest coverage is negative at -5.67, highlighting leverage and coverage risk for investors.

Technical picture and intraday drivers

Momentum indicators show an extreme short-term reading with RSI at 100.00 and ADX at 50.00, suggesting a strong intraday trend. The 50-day average is $11.66 and the 200-day average is $10.81; price above both implies short-term strength. Keltner channel middle sits at $11.93. On-balance volume is 452081061.00, confirming heavy inflows. Short interest and trading flow may be influencing moves; see latest short-interest data on MarketBeat for context source.

Meyka AI grade and forecast

Meyka AI rates WBA with a score out of 100: 59.37 / 100, Grade C+, suggestion HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month target of $13.50, versus the current price of $11.98, implying an upside of 12.71%. Forecasts are model-based projections and not guarantees.

Analyst consensus, peers and catalysts

Brokerage signals show limited coverage with a consensus leaning toward caution; upgrade/downgrade data lists a single sell rating in the snapshot. Peers include Walmart, CVS, and Dollar stores for retail pharmacy comparison. Corporate catalysts include quarterly results, U.S. pharmacy reimbursement updates, and international performance. The company’s inclusion in Dow coverage and market commentary has kept it in headlines; see recent coverage on sector shifts source.

Risks and opportunities for WBA investment

Key risks: high leverage with debt-to-equity 4.04, negative EPS of -7.29, weak interest coverage, and thin free cash flow per share at -0.59. Key opportunities: stable retail pharmacy cash flows, dividend yield 2.09%, multi-channel international business, and cost-savings programs. Short-term holders should monitor volume and the 50-day average. Long-term investors should weigh balance-sheet repair against secular pressures in retail pharmacy.

Final Thoughts

WBA stock is trading pre-market at $11.98 with unusually heavy volume and a clear short-term momentum signal. Valuation shows low price-to-sales at 0.09 and a price-to-book of 1.44, but profitability remains pressured with EPS -7.29 and negative free cash flow per share of -0.59. Meyka AI’s forecast model projects a 12‑month target of $13.50, implying a 12.71% upside from today’s price. That forecast sits between a conservative $10.00 downside scenario and a $15.00 bull scenario if margins and cash flow recover. Our Meyka AI grade of 59.37 (C+, HOLD) reflects mixed fundamentals, sector positioning, and recent trading dynamics. Traders seeking short-term setups should watch the 50-day average at $11.66 and intraday volume spikes. Investors looking beyond 12 months should track quarterly results, debt reduction progress, and pharmacy reimbursement clarity. Forecasts are model-based projections and not guarantees. Meyka AI provides this AI-powered market analysis to frame decisions, not to offer investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.